New healthcare fraud trends managed care organizations need to watch

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/new-healthcare-fraud-trends-managed-care-organizations-need-watch?GUID=A13E56ED-9529-4BD1-98E9-318F5373C18F&rememberme=1&ts=17112017

Related image

 

Even traditional fraud schemes can be difficult to detect, and new methods will only make things more difficult for security teams watching healthcare dollars, says Shimon R. Richmond, special agent in charge at the Miami Regional Office in the Office of Investigations for the Office of the Attorney General.

Richmond gave a presentation on healthcare fraud trends on November 16 at the annual National Healthcare Anti-Fraud Association conference in Orlando, and says hypervigilance is key because obvious red flags are rare.

Where fraud is most prevalent

Richmond says these methods are often based in home health care, personal services, community-based services, and hospice care.

“We see a lot of unnecessary services and billing for services not provided. In the personal care services arena there are a lot of incestuous relationships in terms of who’s providing the care, who’s receiving the care, and who’s billing,” Richmond says. “One really kind of significant theme is pervasive and that’s the overwhelming influence of kickbacks in every area of fraud that we’re seeing.”

Kickbacks can be difficult to detect because this type of fraud often occurs outside of medical systems, he says. Data analytics systems can help, particularly if a system can recognize spikes in billing patterns or from certain providers.

“That’s a red flag. There are those anomalies that we can identify in a proactive manner. But the outside financial arrangements are really something that law enforcement is really only able to get into once we delve into an investigation,” Richmond says.

New fraud trends  

Emerging fraud trends are another challenge when counteracting fraud. It’s difficult to get in front of a new problem that hasn’t been seen before, and the game is always changing, Richmond says.

Recently, Richmond says he has seen an uptick in inappropriate prescriptions for  SUBSYS (fentanyl sublingual spray), which is meant to be prescribed to treat breakthrough pain in cancer patients.

“We’ve seen a huge issue lately where it is being marketed and prescribed to noncancer patients,” Richmond says. “Huge amounts of this drug are being prescribed, but the prescriber is not an oncologist.”

Pharmacies can also be involved in fraudulent activities by searching patient insurance plans to find high-cost prescriptions that can be filled and paid for. The pharmacies then target those consumers to push medications they don’t need, or bill for prescriptions that are never filled.

“A lot of times it’s a bait-and-switch type situation where they’ll do some kind of advertising for a knee brace or some other kind of thing just to get patients to call a number,” Richmond says. Once patients call, they are told the product they were interested in is not available but are offered a more expensive substitute. “There are a lot of marketing companies out there that are acting as lead generators where they are essentially selling to patients the idea of trying out these pains creams or scar creams.”

Hospitals and provider groups in financial distress are also becoming involved in fraud schemes, setting up in-house labs or working with outside labs to generate claims, often for fraudulent genetic testing or urine/drug screens. They may bill for unneeded tests with a kickback, or collect samples that never get tested but are still billed, he says.

Cyber threats and identity theft also continue to be a problem, Richmond says, with a huge spike in the area of telemedicine.

New fraudsters enter the arena

“We are seeing bulk cash transfers, weapons caches, and drug organizations migrating in as they develop their technological abilities and acumen in how to exploit electronic health records,” Richmond says. “This is kind of an evolving threat, and unfortunately, so much of the information is obtainable either online or through an employee that compromises the organization and practice.”

Security teams have to focus on trending information from data on encounters and billing practices, and analyze patterns just to try and keep up.

“I can’t emphasize enough the value of the investments in the analytics and proactive monitoring. That is crucial. Being in the law enforcement arena, a lot of our proactive efforts involve a combination of those analytics and looking for those outliers, or those parts that don’t make sense,” Richmond says. “At the end of the day, it’s all about hypervigilance.

Liquid Gold: Pain Doctors Soak Up Profits By Screening Urine For Drugs

https://khn.org/news/liquid-gold-pain-doctors-soak-up-profits-by-screening-urine-for-drugs/

The cups of urine travel by express mail to the Comprehensive Pain Specialists lab in an industrial park in Brentwood, Tenn., not far from Nashville. Most days bring more than 700 of the little sealed cups from clinics across 10 states, wrapped in red-tagged waste bags. The network treats about 48,000 people each month, and many will be tested for drugs.

Gloved lab techs keep busy inside the cavernous facility, piping smaller urine samples into tubes. First there are tests to detect opiates that patients have been prescribed by CPS doctors. A second set identifies a wide range of drugs, both legal and illegal, in the urine. The doctors’ orders are displayed on computer screens and tracked by electronic medical records. Test results go back to the clinics in four to five days. The urine ends up stored for a month inside a massive walk-in refrigerator.

The high-tech testing lab’s raw material has become liquid gold for the doctors who own Comprehensive Pain Specialists. This testing process, driven by the nation’s epidemic of painkiller addiction, generates profits across the doctor-owned network of 54 clinics, the largest pain-treatment practice in the Southeast. Medicare paid the company at least $11 million for urine and related tests in 2014, when five of its professionals stood among the nation’s top billers. One nurse practitioner at the company’s clinic in Cleveland, Tenn., single-handedly generated $1.1 million in Medicare billings for urine tests that year, according to Medicare records.

Dr. Peter Kroll, one of the founders of CPS and its medical director, billed Medicare $1.8 million for these drug tests in 2015. He said the costly tests are medically justified to monitor patients on pain pills against risks of addiction or even selling of pills on the black market. “I have to know the medicine is safe and you’re taking it,” Kroll, 46, said in an interview. Kroll said that several states in which CPS is active have high rates of opioid use, which requires more urine testing.

Kaiser Health News, with assistance from researchers at the Mayo Clinic, analyzed available billing data from Medicare and private insurance billing nationwide, and found that spending on urine screens and related genetic tests quadrupled from 2011 to 2014 to an estimated $8.5 billion a year — more than the entire budget of the Environmental Protection Agency. The federal government paid providers more to conduct urine drug tests in 2014 than it spent on the four most recommended cancer screenings combined.

Yet there are virtually no national standards regarding who gets tested, for which drugs and how often. Medicare has spent tens of millions of dollars on tests to detect drugs that presented minimal abuse danger for most patients, according to arguments made by government lawyers in court cases that challenge the standing orders to test patients for drugs. Payments have surged for urine tests for street drugs such as cocaine, PCP and ecstasy, which seldom have been detected in tests done on pain patients. In fact, court records show some of those tests showed up positive just 1 percent of the time.

Urine testing has become particularly lucrative for doctors who operate their own labs. In 2014 and 2015, Medicare paid $1 million or more for drug-related tests billed by health professionals at more than 50 pain management practices across the U.S. At a dozen practices, Medicare billings were twice that high.

Thirty-one pain practitioners received 80 percent or more of their Medicare income just from urine testing, which a federal official called a “red flag” that may signal overuse and could lead to a federal investigation.

“We’re focused on the fact that many physicians are making more money on testing than treating patients,” said Jason Mehta, an assistant U.S. attorney in Jacksonville, Fla. “It is troubling to see providers test everyone for every class of drugs every time they come in.”

Sema4, a Mount Sinai spinout, launches with a focus on genomics

Sema4, a Mount Sinai spinout, launches with a focus on genomics

dna, genomics

New York City, New York-based Mount Sinai Health System has launched a new spinout company: Sema4.

The for-profit startup has been created from numerous parts of Mount Sinai’s Department of Genetics and Genomic Sciences and the Icahn Institute for Genomics and Multiscale Biology.

Pronounced “semaphore,” the company will utilize genomic and clinical data to transform overall clinical diagnostics. By combining everything from predictive modeling to open access data, it aims to be able to better treat and diagnose diseases.

Sema4 will be run by Eric Schadt, the chair of the Department of Genetics and Genomic Sciences and the founding director of the Icahn Institute for Genomics and Multiscale Biology.

Schadt initially came to Mount Sinai about five years ago and has since helped grow its footprint in big data and genomics. But the current landscape presented an opportune time to create Sema4.

As genomic testing becomes more complex, Schadt explained, it came down to a few questions for Mount Sinai: “How do we scale all of this? How do we aggregate and manage really large scales of data and compute on it? The decision was that it’s better done as an independent company still in partnership with Sinai,” he told MedCity in a phone interview.

Mount Sinai and Sema4 will continue to be heavily involved with each other. Sema4 is the provider of all genetic testing services for Mount Sinai. And Mount Sinai will play a key role in technology development, data mining and data integration for Sema4.

“We’ll have a very, very intimate relationship,” Schadt said. “But now we are an independent, for-profit company that is presently wholly owned by Mount Sinai.”

Mount Sinai has made a large investment in Sema4 and is currently the company’s sole investor. Over the next 12 to 18 months, the startup will use those funds to grow its business, particularly its sales and marketing teams.

But after time, Sema4 will begin raising additional capital to boost the genetic testing and data sciences portions of its business.

“Once we’re stood up as a company and have our footing that way, we’ll be in a better position to more aggressively pursue the information side, and that’ll take an even bigger investment,” Schadt said.

He did not share any specific numbers with MedCity about how much Sema4 will be looking to raise.

Currently, reproductive health is a major focus area for the startup. But moving forward, Schadt said Sema4 wants to increase its involvement in the oncology space. Additionally, the company has set its sights on using digital health tools to better engage patients.

Prior to Sema4, Mount Sinai’s AppLab and Mount Sinai Innovation Partners launched a startup called Responsive Health for app distribution platform RxUniverse.

Leading researchers recommend major change in prostate cancer treatment

https://www.washingtonpost.com/news/to-your-health/wp/2016/07/06/leading-researchers-recommend-major-change-in-prostate-cancer-treatment/

Leading American and British cancer researchers are urging that all men with advanced prostate cancer strongly consider being tested for inherited gene mutations — both to help steer their treatment and to alert family members who themselves might be at increased risk for a range of cancers.

This new recommendation, which represents a major change in approach, was prompted by a study published Wednesday in the New England Journal of Medicine. The researchers found that almost 12 percent of men with advanced cancer had defects in genes that are designed to fix damage to DNA, compared to 4.6 percent of patients with disease that hadn’t spread.